The Europe Vulvovaginal Candidiasis Treatment Market would witness market growth of 4.2% CAGR during the forecast period (2022-2028).
The need for vulvovaginal candidiasis treatment is growing as a result of the rising prevalence of the disease, which further indicates the rising demand for better treatment options. Also, the growing number of hospital-acquired infections, the continued development of new antifungal drugs, growing healthcare spending, and the advancement in healthcare infrastructure are some of the factors supporting market growth for the vulvovaginal candidiasis treatment market.
The continued increase in the use of antibiotics is resulting high prevalence of vaginal yeast infection among women. Also, the cases of cardiovascular diseases, neurological diseases, cancer as well as gastrointestinal disease have resulted in growing consumption of broad-spectrum antibiotics across the globe which may result in rising cases of vulvovaginal candidiasis. This raises the need for treatment of vulvovaginal candidiasis leading to market growth.
Various advances in the understanding of vulvovaginal candidiasis as an immunopathology, as well as the mechanistic role of the inflammasome, candidalysin, and PRR-mediated signaling at vaginal mucosa, have opened up new paths for scientific exploration. The consideration of vulvovaginal candidiasis as an immunopathology is an inevitable shift. As the incidence of VVC across the globe is expected to rise in the upcoming years, improved treatment modalities and diagnosing facilities will be required in the near future.
In 2019, about 105,200 people had HIV infection in the United Kingdom; out of these, 6600 cases were predicted undiagnosed. Also, obesity continued to be among the region's significant concerns of public health. Being overweight and obese raises the risk of developing various diseases. Obese people are more at risk of insulin resistance and high blood sugar level, and the development of diabetes. The increased blood sugar level could result in overgrowth of Candida, especially in the genitals or bladder. Furthermore, the consumption of antibiotics for the treatment of the urinary tract could also lead to candida-related infection. As a result, the rising prevalence of obesity would further raise the occurrence of vulvovaginal candidiasis in the region.
The Germany market dominated the Europe Vulvovaginal Candidiasis Treatment Market by Country in 2021; thereby, achieving a market value of $88.5 million by 2028. The UK market is exhibiting a CAGR of 3.3% during (2022 - 2028). Additionally, The France market would experience a CAGR of 5% during (2022 - 2028).
Based on Distribution Channel, the market is segmented into Retail Pharmacy, Hospital Pharmacy and Online Pharmacy. Based on Route of Administration, the market is segmented into Oral, Intravenous and Topical. Based on Drug Class, the market is segmented into Fluconazole, Clotrimazole, Terconazole, Terbinafine, Nystatin, Ketoconazole and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
Free Valuable Insights: The Global Vulvovaginal Candidiasis Treatment Market will Hit $1.3 Billion by 2028, at a CAGR of 4.6%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Bayer AG, Bristol Myers Squibb Company, Pfizer, Inc., Astellas Pharma, Inc., Mycovia Pharmaceuticals, Inc. (NovaQuest Capital Management,LLC), Basilea Pharmaceutica Ltd., Scynexis, Inc. and Grupo Ferrer Internacional S.A.
By Distribution Channel
By Route of Administration
By Drug Class
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
